For US Healthcare Professionals only

HemAssist logo

Patient support for ALTUVIIIO®

HemAssist complements the care you provide your patients with support for what’s ahead.


Getting started with ALTUVIIIO

HemAssist works with you and your patients to get them started on ALTUVIIIO as efficiently as possible. Our support begins with the enrollment process. As soon as we receive an enrollment form, we can begin a benefits investigation to determine if your patient is eligible for financial assistance.

Our support includes triaging the prescription to the patient's specialty pharmacy and assisting with medication shipments, providing patients with supplemental infusion training, supporting patients with claims and reimbursements, and more.

Altuviiio product logo

Our support

Decorative wallet icon

Affording ALTUVIIIO

No matter your patient's situation, we are committed to helping them access and afford ALTUVIIIO. The HemAssist team will verify your patient's insurance coverage and determine what financial assistance programs they may be eligible for.

Decorative 1-2-3 steps icon

Starting treatment

The HemAssist team can help your patient get started with ALTUVIIIO right away. We can provide supplemental infusion training and offer tips for building a treatment routine.

Decorative conversation bubble icon

Ongoing support

Our team provides support and guidance to your patient throughout the ALTUVIIIO journey. This includes navigating insurance changes and periodically checking with the patient to support them throughout treatment.

Financial assistance

HemAssist works directly with your patients to help identify programs they may be eligible for.

Copay Assistance Program*

HemAssist may be able to help eligible patients gain access to ALTUVIIIO for as little as $0.

Free Trial Program†

With the Free Trial Program, patients can get their first 30-day supply of treatment generally within 24 to 48 hours with a valid prescription.  While you and your patient are deciding what treatment is right for them, a dedicated Sanofi Case Manager will review their health insurance information and coverage for ALTUVIIIO. Once the enrollment is complete, a dedicated Sanofi Case Manager will contact your patient within 24 hours with next steps.

Patient Assistance Program†

HemAssist's Patient Assistance Program may be available to help eligible ALTUVIIIO patients who are uninsured, underinsured, or experiencing a temporary loss of insurance coverage.

*Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their ALTUVIIIO prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their ALTUVIIIO prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

† Free Trial valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free Trial not valid in Vermont. Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Meet your team

HemAssist works directly with your patients to help identify programs they may be eligible for.

HemAssist team member sitting at a desk with a headset

Clinical Educator (CE)

CEs can answer questions from you or your patients about ALTUVIIIO and can provide patients with helpful support including treatment tips and supplemental administration training.

Portrayal of a smiling man sitting at a desk wearing a headset

Case Managers

Case Managers provide you with personalized insurance investigations and answer questions about financial assistance options for eligible patients. They can help coordinate treatment shipments and assist with reimbursements.

Portrayal of an woman in an office speaking into a headset

Field Reimbursement Managers (FRM)

Our FRMs can help you navigate insurance coverage and provide reimbursement education and solutions.

Ready to enroll a patient in HemAssist?

It takes just a few steps. Enroll online or download and fax an enrollment form. 

INDICATION

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding

LIMITATION OF USE

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS

  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.

ADVERSE REACTIONS

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

INDICATION

IMPORTANT SAFETY INFORMATION

HemAssist Sanofi Support Here for your patients throughout their treatment journey. Call 1-833-723-5463 Monday – Friday 8 AM to 7 PM ET Fax 1-855-398-7634 © 2025 Sanofi. All rights reserved. ALTUVIIIO, HemAssist, and Sanofi are trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2505185-v1.0-08/2025